亚日韩在线中文字幕亚洲,国产在线播放鲁啊鲁视频,张柏芝手扒性器全部图片,亚洲成无码电影在线观看

AR230-r 

(ATCC? CRL-3346?)

Organism Homo sapiens, human

Tissuebone marrow; derived from metastatic site: pleural effusion

Product Format提供形式 frozen 1.0 mL

Morphology hematopoietic

Culture Properties suspension

Biosafety Level1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Diseasechronic myeloid leukemia in blast crisis

Age 年齡 52

Gender 性別 female

Applications This is a clone of the parental AR230 cell line which is resistant to the tyrosine kinase inhibitor imatinib mesylate, and is paired to the AR230-s clone which is resistant to imatinib. The paired AR230-s and AR230-r clones are useful cell line models of sensitivity and resistance to a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia.

Storage Conditions liquid nitrogen vapor phase

Karyotype 44, XX, -11, -14, -17, -17, +mar, inv(1)(p31-32p36) or add(1)(p31-32), -2 or add(2)(p13), del(9)(q22) or der(9)t(9;?)(q11-13;?), der(9)t(9;?)(p13;?)t(9;22) (q34;q11), add(15)(p11), add(18)(q21), der(11;21)(q10;p10), der(22)t(9;22) (q34;q11), +der(22)t(9;22)(q34;q11)

ImagesCell Micrograph of AR230-r, ATCC CRL-3346

Derivation Erythroid-myeloid precursor cell line derived from chronic myelogenous leukemia at blast crisis

Clinical Data 52 years female

Oncogene BCR-ABL of the e19a2 fusion transcript type

Comments 注釋 Chronic Myeloid Leukemia resistant to the tyrosine kinase inhibitor imatinib mesylate

Oncogenes: BCR-ABL of the e19a2 fusion transcript type

Erythroid-Myeloid precursor cell line derived from CML in blast crisis.

Complete Growth MediumThe complete medium for this cell line is RPMI-1640 + 10% FBS + 2 mM L-Glutamine + 1 μM Imatinib Details for preparation of 500 ml of complete media

Medium: 500 mL RPMI-1640 (ATCC 30-2001)

Serum: 56 mL FBS (ATCC 30-2020)

Additive: 5.6 mL L-Glutamine (200 mM, ATCC 30-2214)

0.5 mL 1 mM Imatinib working stock (see below)

To prepare 1 mM Imatinib working stock, aseptically combine the following:

25 mg Imatinib (Sigma catalog # CDS022173-25MG) into 45 mL Culture grade water (Hyclone catalog # SH30529

Note 注釋 : Supplement Imatinib at each reseed rather than including in culture medium bottle. The shelf life for Imatinib in culture medium is unknown, so do not use a prepared culture medium bottle for more than 30 days. Additionally, if cell growth appears to slow during cell line expansion, prepare a new bottle of fresh medium.

Subculturing Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2.5 to 3.5 X 105 cells/mL and maintain between 2 X 105 and 1X 106 cells/mL.

Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density).

Culture Conditions

Atmosphere 需氧情況: air, 95%; carbon dioxide (CO2), 5%

Temperature 培養(yǎng)溫度: 37°C

Volume容量 1.0 mL

STR Profile Amelogenin: X

CSF1PO: 10, 12

D13S317: 8, 10

D16S539: 9, 13

D5S818: 11, 13

D7S820: 10, 11

THO1: 6

TPOX: 11

vWA: 16, 20

Sterility TestsBacteria and Yeast: No growth

Mycoplasma: No growth

Population Doubling Time Approximately 30-48 hours

Name of Depositor 寄存人 J Vaz deMelo, University of Adelaide, Australia

Year of Origin收藏年份 1999

References 參考文獻(xiàn) Mahon FX, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96(3): 1070-1079, 2000 PubMed: 10910924

Wada H, et al. Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein. Cancer Res 55 (14): 3192-3196, 1995. PubMed: 7606740

Drexler HG, et al. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. Leuk Res 23 (3): 207-215, 1999. PubMed: 10071072